-
ZZZQUIL NATURA MANGO & BAN30PAST ₦19,722.00 -
-
ACIVIR DT 400MG TAB 5`S ₦3,071.25 -
CLINDAFIN A Gel 20gm ₦37,400.00 -
Arcolane 2% Scalp Solution, 60ml ₦3,200.00 -
-
-
OZEPRO 1% TUBE OF 5GM CREAM ₦2,554.50 -
Natures Aid Cod Liver Oil Omega 3 - 500ml ₦39,000.00 -
CARIPAYA TAB 10`S ₦9,673.25
-
Sale
Atasin 40 mgAtasin 40 mg is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo-B) and triglycerides levels in following diseases when response to diet and other non-pharmacological measures is inadequate. To reduce total cholesterol and LDL cholesterol in patients with heterozygous and homozygous familial hypercholesterolaemia. To reduce elevated cholesterol and triglycerides in patient with mixed dyslipidemia (Fredrickson Type Ia and Ib). For the treatment of patients with elevated serum triglyceride levels in hypertriglyceridaemia (Fredrickson Type IV). For the treatment of patients with dysbetalipoproteinaemia (Fredrickson Type III). To reduce cardiac ischaemic events in patients with asymptomatic or mild to moderate symptomatic coronary artery disease with elevated LDL-cholesterol level. To reduce total and LDL-cholesterol concentrations patients with hypercholesterolemia associated with or exacerbated by diabetes mellitus or renal transplantation.Theropeutic ClassOther Anti-anginal & Anti-ischaemic drugs, StatinsPharmacologyAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.Dosage & Administration of Atasin 40 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Dosage of Atasin 40 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Interaction of Atasin 40 mgThe risk of myopathy during treatment with Atorvastatin is increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, azole antifungals and niacin. No clinically significant interactions were seen when Atorvastatin was administered with antihypertensives or hypoglycemic agents. Patients should be closely monitored if Atorvastatin is added to digoxin, erythromycin, oral contraceptives, colestipol, antacid and warfarin.ContraindicationsAtasin 40 mg should not be used in patient with hypersensitivity to any component of this medication. It's contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. It is also contraindicated in patient with history of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors.Side Effects of Atasin 40 mgAtasin 40 mg is generally well-tolerated. The most frequent side effects related to Atasin 40 mg are constipation, flatulence, dyspepsia, abdominal pain. Other side effects includes infection, headache, back pain, rash, asthenia, arthralgia, myalgia.Pregnancy & LactationAtasin 40 mg is contraindicated in pregnancy and while breast-feeding. Women of child bearing potential should use appropriate contraceptive measures during Atorvastatin therapy. If the woman become pregnant while taking Atasin 40 mg, it should be discontinued.Precautions & WarningsLiver effects: Liver function tests should be performed before the initiation of treatment and periodically thereafter. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.Overdose Effects of Atasin 40 mgSpecific treatment is not available for atorvastatin overdose. The patient should be treated symptomatically and supportive measures instituted, as required. Liver function tests should be performed and serum CK levels should be monitored. Due to extensive atorvastatin binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Use In Special PopulationsGeriatric Use: Of the 39,828 patients who received Atorvastatin in clinicalstudies, 15,813 (40%) were ?65 years old and 2,800 (7%) were ?75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinicalexperience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (?65 years) is a predisposing factor for myopathy, Atorvastatin?should be prescribed with caution in the elderly.Hepatic Impairment: Atorvastatin?is contraindicated in patients with active liver disease whichmay include unexplained persistent elevations in hepatic transaminase levelsDrug ClassesOther Anti-anginal & Anti-ischaemic drugs, StatinsMode Of ActionAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.PregnancyPregnancy: Atorvastatin is contraindicated during pregnancy. Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction. Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atorvastatin should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with atorvastatin should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnantLactation: It is not known whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. Because of the potential for serious adverse reactions, women taking atorvastatin should not breastfeed their infants. Atorvastatin is contraindicated during breastfeeding.Pediatric UsesHepatic impairment: Atasin 40 mg should be used with caution in patients with hepatic impairment. Pediatric use: For patients aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day with titration up to 20 mg per day. Atasin 40 mg is not indicated in the treatment of patients below the age of 10 years.Atasin40 mg
Original price was: ₦15,400.00.₦13,860.00Current price is: ₦13,860.00. -
SaleAtova EZ 10 mg+10 mgTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted ... Read moreTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.Primary Hyperlipidemia: This tablet is indicated for the reduction of elevated total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.Homozygous Familial Hypercholesterolemia (HoFH): This tablet is indicated for the reduction of elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.Dosage of Atova EZ 10 mg+10 mgThe dosage range is 10/10 mg to 80/20 mg daily. The recommended starting dose is 10/10 mg or 20/10 mg daily. This can be administered as a single dose at any time of the day, with or without food. The recommended starting dose for patients who require a larger reduction in LDL-C (greater than 55%) is 40/10 mg daily. After initiation and/or upon titration of this medicine, lipid levels should be analyzed within 2 or more weeks and dosage adjusted accordingly.Patients with Homozygous Familial Hypercholesterolemia: The dosage in patients with homozygous familial hypercholesterolemia is 40/10 mg or 80/10 mg daily. This should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable. Patients with Hepatic Impairment: This is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels. Patients with Renal Impairment: A history of renal impairment may be a risk factor for statin-associated myopathy. These patients need closer monitoring for skeletal muscle effects. In patients with renal impairment, no dosage adjustment is necessary.Interaction of Atova EZ 10 mg+10 mgThe risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole). The coadministration of this combination with cyclosporine should be avoided. Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of this combination with gemfibrozil should be avoided. The risk of skeletal muscle effects may be enhanced when this combination is used in combination with niacin. Patients taking digoxin should be monitored appropriately. The increase in AUC values for norethindrone and ethinyl estradiol should be considered when selecting an oral contraceptive for a woman taking this combination. Caution should be exercised when prescribing this combination with colchicine. If this combination is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.ContraindicationsActive liver disease or unexplained persistent elevations of hepatic transaminase levels. Hypersensitivity to any component of this preparation.Side Effects of Atova EZ 10 mg+10 mgCommon side effects are rhabdomyolysis, myopathy, liver enzyme abnormalities, myalgia, abdominal pain, increased hepatic enzymes.Precautions & WarningsCases of myopathy, including rhabdomyolysis, have been reported with atorvastatin coadministered with colchicine, and caution should be exercised when prescribing this combination with colchicine. This combination therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis.Liver Enzymes: It is recommended that liver enzyme tests be obtained prior to initiating therapy with this combination and repeated as clinically indicated. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with this combination, promptly interrupt therapy. If an alternate etiology is not found, do not restart this combination. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of this combination.Endocrine Function: Caution should be exercised if this combination is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.Overdose Effects of Atova EZ 10 mg+10 mgNo specific treatment of overdosage can be recommended. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.Storage ConditionsDo not store above 30?C. Keep in a dry place. Protect from light and keep out of the reach of children.Drug ClassesOther lipid regulating drugsMode Of ActionAtorvastatin: In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles.Ezetimibe: Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. In a 2-week clinical study in 18 hypercholesterolemic patients, ezetimibe inhibited intestinal cholesterol absorption by 54%, compared with placebo. Ezetimibe had no clinically meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E and did not impair adrenocortical steroid hormone production. Ezetimibe does not inhibit cholesterol synthesis in the liver or increase bile acid excretion. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of statins.PregnancyPregnancy Category X. This tablet is contraindicated in women who are or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy. Lipid-lowering drugs offer no benefit during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy. It is not known whether atorvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk.Pediatric UsesPediatric Use: Safety and effectiveness have not been established in pediatric patients.Geriatric Use: In geriatric patients, no dosage adjustment is necessary.
Atova EZ10 mg+10 mg
Original price was: ₦11,550.00.₦10,395.00Current price is: ₦10,395.00. -
SaleAtova Ez 20 mg+10 mgTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted ... Read moreTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.Primary Hyperlipidemia: This tablet is indicated for the reduction of elevated total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.Homozygous Familial Hypercholesterolemia (HoFH): This tablet is indicated for the reduction of elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.Dosage of Atova Ez 20 mg+10 mgThe dosage range is 10/10 mg to 80/20 mg daily. The recommended starting dose is 10/10 mg or 20/10 mg daily. This can be administered as a single dose at any time of the day, with or without food. The recommended starting dose for patients who require a larger reduction in LDL-C (greater than 55%) is 40/10 mg daily. After initiation and/or upon titration of this medicine, lipid levels should be analyzed within 2 or more weeks and dosage adjusted accordingly.Patients with Homozygous Familial Hypercholesterolemia: The dosage in patients with homozygous familial hypercholesterolemia is 40/10 mg or 80/10 mg daily. This should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable. Patients with Hepatic Impairment: This is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels. Patients with Renal Impairment: A history of renal impairment may be a risk factor for statin-associated myopathy. These patients need closer monitoring for skeletal muscle effects. In patients with renal impairment, no dosage adjustment is necessary.Interaction of Atova Ez 20 mg+10 mgThe risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole). The coadministration of this combination with cyclosporine should be avoided. Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of this combination with gemfibrozil should be avoided. The risk of skeletal muscle effects may be enhanced when this combination is used in combination with niacin. Patients taking digoxin should be monitored appropriately. The increase in AUC values for norethindrone and ethinyl estradiol should be considered when selecting an oral contraceptive for a woman taking this combination. Caution should be exercised when prescribing this combination with colchicine. If this combination is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.ContraindicationsActive liver disease or unexplained persistent elevations of hepatic transaminase levels. Hypersensitivity to any component of this preparation.Side Effects of Atova Ez 20 mg+10 mgCommon side effects are rhabdomyolysis, myopathy, liver enzyme abnormalities, myalgia, abdominal pain, increased hepatic enzymes.Precautions & WarningsCases of myopathy, including rhabdomyolysis, have been reported with atorvastatin coadministered with colchicine, and caution should be exercised when prescribing this combination with colchicine. This combination therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis.Liver Enzymes: It is recommended that liver enzyme tests be obtained prior to initiating therapy with this combination and repeated as clinically indicated. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with this combination, promptly interrupt therapy. If an alternate etiology is not found, do not restart this combination. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of this combination.Endocrine Function: Caution should be exercised if this combination is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.Overdose Effects of Atova Ez 20 mg+10 mgNo specific treatment of overdosage can be recommended. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.Storage ConditionsDo not store above 30?C. Keep in a dry place. Protect from light and keep out of the reach of children.Drug ClassesOther lipid regulating drugsMode Of ActionAtorvastatin: In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles.Ezetimibe: Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. In a 2-week clinical study in 18 hypercholesterolemic patients, ezetimibe inhibited intestinal cholesterol absorption by 54%, compared with placebo. Ezetimibe had no clinically meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E and did not impair adrenocortical steroid hormone production. Ezetimibe does not inhibit cholesterol synthesis in the liver or increase bile acid excretion. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of statins.PregnancyPregnancy Category X. This tablet is contraindicated in women who are or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy. Lipid-lowering drugs offer no benefit during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy. It is not known whether atorvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk.Pediatric UsesPediatric Use: Safety and effectiveness have not been established in pediatric patients.Geriatric Use: In geriatric patients, no dosage adjustment is necessary.
Atova Ez20 mg+10 mg
Original price was: ₦18,150.00.₦16,335.00Current price is: ₦16,335.00. -
SaleAtova 10 mgAtova 10 mg is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo-B) and triglycerides levels in following diseases when response to diet and other non-pharmacological measures is inadequate. To reduce total cholesterol and LDL cholesterol in patients with heterozygous and homozygous familial hypercholesterolaemia. To reduce elevated cholesterol and triglycerides in patient with mixed dyslipidemia (Fredrickson Type Ia and Ib). For the treatment of patients with elevated serum triglyceride levels in hypertriglyceridaemia (Fredrickson Type IV). For the treatment of patients with dysbetalipoproteinaemia (Fredrickson Type III). To reduce cardiac ischaemic events in patients with asymptomatic or mild to moderate symptomatic coronary artery disease with elevated LDL-cholesterol level. To reduce total and LDL-cholesterol concentrations patients with hypercholesterolemia associated with or exacerbated by diabetes mellitus or renal transplantation.Theropeutic ClassOther Anti-anginal & Anti-ischaemic drugs, StatinsPharmacologyAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.Dosage & Administration of Atova 10 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Dosage of Atova 10 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Interaction of Atova 10 mgThe risk of myopathy during treatment with Atorvastatin is increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, azole antifungals and niacin. No clinically significant interactions were seen when Atorvastatin was administered with antihypertensives or hypoglycemic agents. Patients should be closely monitored if Atorvastatin is added to digoxin, erythromycin, oral contraceptives, colestipol, antacid and warfarin.ContraindicationsAtova 10 mg should not be used in patient with hypersensitivity to any component of this medication. It's contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. It is also contraindicated in patient with history of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors.Side Effects of Atova 10 mgAtova 10 mg is generally well-tolerated. The most frequent side effects related to Atova 10 mg are constipation, flatulence, dyspepsia, abdominal pain. Other side effects includes infection, headache, back pain, rash, asthenia, arthralgia, myalgia.Pregnancy & LactationAtova 10 mg is contraindicated in pregnancy and while breast-feeding. Women of child bearing potential should use appropriate contraceptive measures during Atorvastatin therapy. If the woman become pregnant while taking Atova 10 mg, it should be discontinued.Precautions & WarningsLiver effects: Liver function tests should be performed before the initiation of treatment and periodically thereafter. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.Overdose Effects of Atova 10 mgSpecific treatment is not available for atorvastatin overdose. The patient should be treated symptomatically and supportive measures instituted, as required. Liver function tests should be performed and serum CK levels should be monitored. Due to extensive atorvastatin binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Use In Special PopulationsGeriatric Use: Of the 39,828 patients who received Atorvastatin in clinicalstudies, 15,813 (40%) were ?65 years old and 2,800 (7%) were ?75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinicalexperience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (?65 years) is a predisposing factor for myopathy, Atorvastatin?should be prescribed with caution in the elderly.Hepatic Impairment: Atorvastatin?is contraindicated in patients with active liver disease whichmay include unexplained persistent elevations in hepatic transaminase levelsDrug ClassesOther Anti-anginal & Anti-ischaemic drugs, StatinsMode Of ActionAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.PregnancyPregnancy: Atorvastatin is contraindicated during pregnancy. Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction. Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atorvastatin should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with atorvastatin should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnantLactation: It is not known whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. Because of the potential for serious adverse reactions, women taking atorvastatin should not breastfeed their infants. Atorvastatin is contraindicated during breastfeeding.Pediatric UsesHepatic impairment: Atova 10 mg should be used with caution in patients with hepatic impairment. Pediatric use: For patients aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day with titration up to 20 mg per day. Atova 10 mg is not indicated in the treatment of patients below the age of 10 years.Q: What is Atova 10mg? Atova 10mg is a brand name for atorvastatin, used to lower cholesterol. People with high cholesterol or a high risk of heart disease can take the medicine. You can also take it for high triglycerides (fats) levels.? Q: How should I take Atova 10mg? Atova 10mg should be taken by mouth once daily, at the same time each day. It can be taken with or without food. Q: What are the side effects of Atova 10mg? Atova 10mg has some side-effects like nausea, weakness, muscle pain, stomach pain, etc. These side effects are mild and may subside by themselves.? Q: How long does it take for Atova 10mg to work? Atova 10mg usually starts to work within a few weeks of taking it. However, you may need to take it for 2 months to see the full benefits of the medication. Q: Can I stop taking Atova 10mg if I feel better? No, you should not stop taking Atova 10mg without talking to your doctor. Stopping suddenly can make your cholesterol levels go back up.
Atova10 mg
Original price was: ₦9,900.00.₦8,910.00Current price is: ₦8,910.00. -
SaleAtova 20 mgAtova 20 mg is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo-B) and triglycerides levels in following diseases when response to diet and other non-pharmacological measures is inadequate. To reduce total cholesterol and LDL cholesterol in patients with heterozygous and homozygous familial hypercholesterolaemia. To reduce elevated cholesterol and triglycerides in patient with mixed dyslipidemia (Fredrickson Type Ia and Ib). For the treatment of patients with elevated serum triglyceride levels in hypertriglyceridaemia (Fredrickson Type IV). For the treatment of patients with dysbetalipoproteinaemia (Fredrickson Type III). To reduce cardiac ischaemic events in patients with asymptomatic or mild to moderate symptomatic coronary artery disease with elevated LDL-cholesterol level. To reduce total and LDL-cholesterol concentrations patients with hypercholesterolemia associated with or exacerbated by diabetes mellitus or renal transplantation.Theropeutic ClassOther Anti-anginal & Anti-ischaemic drugs, StatinsPharmacologyAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.Dosage & Administration of Atova 20 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Dosage of Atova 20 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Interaction of Atova 20 mgThe risk of myopathy during treatment with Atorvastatin is increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, azole antifungals and niacin. No clinically significant interactions were seen when Atorvastatin was administered with antihypertensives or hypoglycemic agents. Patients should be closely monitored if Atorvastatin is added to digoxin, erythromycin, oral contraceptives, colestipol, antacid and warfarin.ContraindicationsAtova 20 mg should not be used in patient with hypersensitivity to any component of this medication. It's contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. It is also contraindicated in patient with history of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors.Side Effects of Atova 20 mgAtova 20 mg is generally well-tolerated. The most frequent side effects related to Atova 20 mg are constipation, flatulence, dyspepsia, abdominal pain. Other side effects includes infection, headache, back pain, rash, asthenia, arthralgia, myalgia.Pregnancy & LactationAtova 20 mg is contraindicated in pregnancy and while breast-feeding. Women of child bearing potential should use appropriate contraceptive measures during Atorvastatin therapy. If the woman become pregnant while taking Atova 20 mg, it should be discontinued.Precautions & WarningsLiver effects: Liver function tests should be performed before the initiation of treatment and periodically thereafter. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.Overdose Effects of Atova 20 mgSpecific treatment is not available for atorvastatin overdose. The patient should be treated symptomatically and supportive measures instituted, as required. Liver function tests should be performed and serum CK levels should be monitored. Due to extensive atorvastatin binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Use In Special PopulationsGeriatric Use: Of the 39,828 patients who received Atorvastatin in clinicalstudies, 15,813 (40%) were ?65 years old and 2,800 (7%) were ?75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinicalexperience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (?65 years) is a predisposing factor for myopathy, Atorvastatin?should be prescribed with caution in the elderly.Hepatic Impairment: Atorvastatin?is contraindicated in patients with active liver disease whichmay include unexplained persistent elevations in hepatic transaminase levelsDrug ClassesOther Anti-anginal & Anti-ischaemic drugs, StatinsMode Of ActionAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.PregnancyPregnancy: Atorvastatin is contraindicated during pregnancy. Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction. Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atorvastatin should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with atorvastatin should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnantLactation: It is not known whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. Because of the potential for serious adverse reactions, women taking atorvastatin should not breastfeed their infants. Atorvastatin is contraindicated during breastfeeding.Pediatric UsesHepatic impairment: Atova 20 mg should be used with caution in patients with hepatic impairment. Pediatric use: For patients aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day with titration up to 20 mg per day. Atova 20 mg is not indicated in the treatment of patients below the age of 10 years.
Atova20 mg
Original price was: ₦16,500.00.₦14,850.00Current price is: ₦14,850.00. -
SaleAtova 40 mgAtova 40 mg is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo-B) and triglycerides levels in following diseases when response to diet and other non-pharmacological measures is inadequate. To reduce total cholesterol and LDL cholesterol in patients with heterozygous and homozygous familial hypercholesterolaemia. To reduce elevated cholesterol and triglycerides in patient with mixed dyslipidemia (Fredrickson Type Ia and Ib). For the treatment of patients with elevated serum triglyceride levels in hypertriglyceridaemia (Fredrickson Type IV). For the treatment of patients with dysbetalipoproteinaemia (Fredrickson Type III). To reduce cardiac ischaemic events in patients with asymptomatic or mild to moderate symptomatic coronary artery disease with elevated LDL-cholesterol level. To reduce total and LDL-cholesterol concentrations patients with hypercholesterolemia associated with or exacerbated by diabetes mellitus or renal transplantation.Theropeutic ClassOther Anti-anginal & Anti-ischaemic drugs, StatinsPharmacologyAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.Dosage & Administration of Atova 40 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Dosage of Atova 40 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Interaction of Atova 40 mgThe risk of myopathy during treatment with Atorvastatin is increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, azole antifungals and niacin. No clinically significant interactions were seen when Atorvastatin was administered with antihypertensives or hypoglycemic agents. Patients should be closely monitored if Atorvastatin is added to digoxin, erythromycin, oral contraceptives, colestipol, antacid and warfarin.ContraindicationsAtova 40 mg should not be used in patient with hypersensitivity to any component of this medication. It's contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. It is also contraindicated in patient with history of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors.Side Effects of Atova 40 mgAtova 40 mg is generally well-tolerated. The most frequent side effects related to Atova 40 mg are constipation, flatulence, dyspepsia, abdominal pain. Other side effects includes infection, headache, back pain, rash, asthenia, arthralgia, myalgia.Pregnancy & LactationAtova 40 mg is contraindicated in pregnancy and while breast-feeding. Women of child bearing potential should use appropriate contraceptive measures during Atorvastatin therapy. If the woman become pregnant while taking Atova 40 mg, it should be discontinued.Precautions & WarningsLiver effects: Liver function tests should be performed before the initiation of treatment and periodically thereafter. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.Overdose Effects of Atova 40 mgSpecific treatment is not available for atorvastatin overdose. The patient should be treated symptomatically and supportive measures instituted, as required. Liver function tests should be performed and serum CK levels should be monitored. Due to extensive atorvastatin binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Use In Special PopulationsGeriatric Use: Of the 39,828 patients who received Atorvastatin in clinicalstudies, 15,813 (40%) were ?65 years old and 2,800 (7%) were ?75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinicalexperience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (?65 years) is a predisposing factor for myopathy, Atorvastatin?should be prescribed with caution in the elderly.Hepatic Impairment: Atorvastatin?is contraindicated in patients with active liver disease whichmay include unexplained persistent elevations in hepatic transaminase levelsDrug ClassesOther Anti-anginal & Anti-ischaemic drugs, StatinsMode Of ActionAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.PregnancyPregnancy: Atorvastatin is contraindicated during pregnancy. Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction. Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atorvastatin should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with atorvastatin should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnantLactation: It is not known whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. Because of the potential for serious adverse reactions, women taking atorvastatin should not breastfeed their infants. Atorvastatin is contraindicated during breastfeeding.Pediatric UsesHepatic impairment: Atova 40 mg should be used with caution in patients with hepatic impairment. Pediatric use: For patients aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day with titration up to 20 mg per day. Atova 40 mg is not indicated in the treatment of patients below the age of 10 years.
Atova40 mg
Original price was: ₦15,400.00.₦13,860.00Current price is: ₦13,860.00. -
SaleAttentin 10 mgAttention deficit hyperactivity disorder (ADHD).Theropeutic ClassCNS stimulant drugsPharmacologyThe precise mechanism by which Atomoxetine produces its therapeutic effects in Attention Deficit Hyperactivity Disorder (ADHD) is unknown. But, it is thought to be related to selective inhibition of the pre-synaptic nor-epinephrine transporter. Atomoxetine is well-absorbed after oral administration and is minimally affected by food. It is eliminated primarily by oxidative metabolism through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway.Dosage & Administration of Attentin 10 mgAdult & adolescents->70 kg: Initially: 40 mg/day for at least 7 days. Maintenance: 80 mg/day. Max: 100 mg/day. Children & adolescents-Up to 70 kg: Initially: 0.5 mg/kg/day for at least 7 days. Maintenance: 1.2 mg/kg/day. Max: 1.8 mg/kg/day. Dosage of Attentin 10 mgAdult & adolescents->70 kg: Initially: 40 mg/day for at least 7 days. Maintenance: 80 mg/day. Max: 100 mg/day. Children & adolescents-Up to 70 kg: Initially: 0.5 mg/kg/day for at least 7 days. Maintenance: 1.2 mg/kg/day. Max: 1.8 mg/kg/day. Interaction of Attentin 10 mgAlbuterol, CYP2D6 inhibitors & antihypertensive agents interact with Atomoxetine.Contraindications Hypersensitivity to Atomoxetine Concomitant use with Monoamine oxidase inhibitors (MAOIs). Narrow-angle glaucoma. Severe cardiovascular?or cerebrovascular disorders. History of pheochromocytoma. Side Effects of Attentin 10 mgDecreased appetite; headache; nausea; increased BP & heart rate; Insomnia; dry mouth in adults; Somnolence; abdominal pain; vomiting in children.Pregnancy & LactationPregnancy?Category C. Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.Precautions & WarningsAtomoxetine should be used with caution in patients with a history of seizures. Atomoxetine can affect heart rate and blood pressure. It is recommended that the heart rate and blood pressure be measured before treatment is started and periodically during treatment to detect possible clinically important increases. Most patients taking Atomoxetine experience a modest increase in heart rateOverdose Effects of Attentin 10 mgThe most commonly reported gastrointestinal symptoms including somnolence, dizziness, tremor, and abnormal behaviour. Hyperactivity and agitation have also been reported. Signs and symptoms consistent with mild to moderate sympatheticnervous system activation (e.g. tachycardia, blood pressure increased, mydriasis, dry mouth) were also observed. Most events were mild to moderate. In some cases of overdose involving Atomoxetine, seizures and very rarely QT prolongation have been reported. There is limited clinical trial experience with Atomoxetine overdose. No fatal overdoses occurred in clinical trials.Storage ConditionsStore in a cool and dry place, protected from light and moisture.Use In Special PopulationsPediatric use: The pharmacokinetics of Atomoxetine have not been evaluated in children under 6 years of age.Drug ClassesCNS stimulant drugsMode Of ActionThe precise mechanism by which Atomoxetine produces its therapeutic effects in Attention Deficit Hyperactivity Disorder (ADHD) is unknown. But, it is thought to be related to selective inhibition of the pre-synaptic nor-epinephrine transporter. Atomoxetine is well-absorbed after oral administration and is minimally affected by food. It is eliminated primarily by oxidative metabolism through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway.PregnancyPregnancy?Category C. Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.Pediatric UsesPediatric use: The pharmacokinetics of Atomoxetine have not been evaluated in children under 6 years of age.
Attentin10 mg
Original price was: ₦440.00.₦396.00Current price is: ₦396.00. -
SaleATV Eze 10 mg+10 mgTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted ... Read moreTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.Primary Hyperlipidemia: This tablet is indicated for the reduction of elevated total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.Homozygous Familial Hypercholesterolemia (HoFH): This tablet is indicated for the reduction of elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.Dosage of ATV Eze 10 mg+10 mgThe dosage range is 10/10 mg to 80/20 mg daily. The recommended starting dose is 10/10 mg or 20/10 mg daily. This can be administered as a single dose at any time of the day, with or without food. The recommended starting dose for patients who require a larger reduction in LDL-C (greater than 55%) is 40/10 mg daily. After initiation and/or upon titration of this medicine, lipid levels should be analyzed within 2 or more weeks and dosage adjusted accordingly.Patients with Homozygous Familial Hypercholesterolemia: The dosage in patients with homozygous familial hypercholesterolemia is 40/10 mg or 80/10 mg daily. This should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable. Patients with Hepatic Impairment: This is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels. Patients with Renal Impairment: A history of renal impairment may be a risk factor for statin-associated myopathy. These patients need closer monitoring for skeletal muscle effects. In patients with renal impairment, no dosage adjustment is necessary.Interaction of ATV Eze 10 mg+10 mgThe risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole). The coadministration of this combination with cyclosporine should be avoided. Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of this combination with gemfibrozil should be avoided. The risk of skeletal muscle effects may be enhanced when this combination is used in combination with niacin. Patients taking digoxin should be monitored appropriately. The increase in AUC values for norethindrone and ethinyl estradiol should be considered when selecting an oral contraceptive for a woman taking this combination. Caution should be exercised when prescribing this combination with colchicine. If this combination is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.ContraindicationsActive liver disease or unexplained persistent elevations of hepatic transaminase levels. Hypersensitivity to any component of this preparation.Side Effects of ATV Eze 10 mg+10 mgCommon side effects are rhabdomyolysis, myopathy, liver enzyme abnormalities, myalgia, abdominal pain, increased hepatic enzymes.Precautions & WarningsCases of myopathy, including rhabdomyolysis, have been reported with atorvastatin coadministered with colchicine, and caution should be exercised when prescribing this combination with colchicine. This combination therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis.Liver Enzymes: It is recommended that liver enzyme tests be obtained prior to initiating therapy with this combination and repeated as clinically indicated. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with this combination, promptly interrupt therapy. If an alternate etiology is not found, do not restart this combination. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of this combination.Endocrine Function: Caution should be exercised if this combination is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.Overdose Effects of ATV Eze 10 mg+10 mgNo specific treatment of overdosage can be recommended. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.Storage ConditionsDo not store above 30?C. Keep in a dry place. Protect from light and keep out of the reach of children.Drug ClassesOther lipid regulating drugsMode Of ActionAtorvastatin: In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles.Ezetimibe: Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. In a 2-week clinical study in 18 hypercholesterolemic patients, ezetimibe inhibited intestinal cholesterol absorption by 54%, compared with placebo. Ezetimibe had no clinically meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E and did not impair adrenocortical steroid hormone production. Ezetimibe does not inhibit cholesterol synthesis in the liver or increase bile acid excretion. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of statins.PregnancyPregnancy Category X. This tablet is contraindicated in women who are or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy. Lipid-lowering drugs offer no benefit during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy. It is not known whether atorvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk.Pediatric UsesPediatric Use: Safety and effectiveness have not been established in pediatric patients.Geriatric Use: In geriatric patients, no dosage adjustment is necessary.
ATV Eze10 mg+10 mg
Original price was: ₦5,500.00.₦4,950.00Current price is: ₦4,950.00. -
SaleATV Eze 20 mg+10 mgTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted ... Read moreTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.Primary Hyperlipidemia: This tablet is indicated for the reduction of elevated total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.Homozygous Familial Hypercholesterolemia (HoFH): This tablet is indicated for the reduction of elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.Dosage of ATV Eze 20 mg+10 mgThe dosage range is 10/10 mg to 80/20 mg daily. The recommended starting dose is 10/10 mg or 20/10 mg daily. This can be administered as a single dose at any time of the day, with or without food. The recommended starting dose for patients who require a larger reduction in LDL-C (greater than 55%) is 40/10 mg daily. After initiation and/or upon titration of this medicine, lipid levels should be analyzed within 2 or more weeks and dosage adjusted accordingly.Patients with Homozygous Familial Hypercholesterolemia: The dosage in patients with homozygous familial hypercholesterolemia is 40/10 mg or 80/10 mg daily. This should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable. Patients with Hepatic Impairment: This is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels. Patients with Renal Impairment: A history of renal impairment may be a risk factor for statin-associated myopathy. These patients need closer monitoring for skeletal muscle effects. In patients with renal impairment, no dosage adjustment is necessary.Interaction of ATV Eze 20 mg+10 mgThe risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole). The coadministration of this combination with cyclosporine should be avoided. Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of this combination with gemfibrozil should be avoided. The risk of skeletal muscle effects may be enhanced when this combination is used in combination with niacin. Patients taking digoxin should be monitored appropriately. The increase in AUC values for norethindrone and ethinyl estradiol should be considered when selecting an oral contraceptive for a woman taking this combination. Caution should be exercised when prescribing this combination with colchicine. If this combination is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.ContraindicationsActive liver disease or unexplained persistent elevations of hepatic transaminase levels. Hypersensitivity to any component of this preparation.Side Effects of ATV Eze 20 mg+10 mgCommon side effects are rhabdomyolysis, myopathy, liver enzyme abnormalities, myalgia, abdominal pain, increased hepatic enzymes.Precautions & WarningsCases of myopathy, including rhabdomyolysis, have been reported with atorvastatin coadministered with colchicine, and caution should be exercised when prescribing this combination with colchicine. This combination therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis.Liver Enzymes: It is recommended that liver enzyme tests be obtained prior to initiating therapy with this combination and repeated as clinically indicated. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with this combination, promptly interrupt therapy. If an alternate etiology is not found, do not restart this combination. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of this combination.Endocrine Function: Caution should be exercised if this combination is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.Overdose Effects of ATV Eze 20 mg+10 mgNo specific treatment of overdosage can be recommended. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.Storage ConditionsDo not store above 30?C. Keep in a dry place. Protect from light and keep out of the reach of children.Drug ClassesOther lipid regulating drugsMode Of ActionAtorvastatin: In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles.Ezetimibe: Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. In a 2-week clinical study in 18 hypercholesterolemic patients, ezetimibe inhibited intestinal cholesterol absorption by 54%, compared with placebo. Ezetimibe had no clinically meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E and did not impair adrenocortical steroid hormone production. Ezetimibe does not inhibit cholesterol synthesis in the liver or increase bile acid excretion. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of statins.PregnancyPregnancy Category X. This tablet is contraindicated in women who are or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy. Lipid-lowering drugs offer no benefit during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy. It is not known whether atorvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk.Pediatric UsesPediatric Use: Safety and effectiveness have not been established in pediatric patients.Geriatric Use: In geriatric patients, no dosage adjustment is necessary.
ATV Eze20 mg+10 mg
Original price was: ₦8,250.00.₦7,425.00Current price is: ₦7,425.00. -
SaleATV 10 mgATV 10 mg is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo-B) and triglycerides levels in following diseases when response to diet and other non-pharmacological measures is inadequate. To reduce total cholesterol and LDL cholesterol in patients with heterozygous and homozygous familial hypercholesterolaemia. To reduce elevated cholesterol and triglycerides in patient with mixed dyslipidemia (Fredrickson Type Ia and Ib). For the treatment of patients with elevated serum triglyceride levels in hypertriglyceridaemia (Fredrickson Type IV). For the treatment of patients with dysbetalipoproteinaemia (Fredrickson Type III). To reduce cardiac ischaemic events in patients with asymptomatic or mild to moderate symptomatic coronary artery disease with elevated LDL-cholesterol level. To reduce total and LDL-cholesterol concentrations patients with hypercholesterolemia associated with or exacerbated by diabetes mellitus or renal transplantation.Theropeutic ClassOther Anti-anginal & Anti-ischaemic drugs, StatinsPharmacologyAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.Dosage & Administration of ATV 10 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Dosage of ATV 10 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Interaction of ATV 10 mgThe risk of myopathy during treatment with Atorvastatin is increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, azole antifungals and niacin. No clinically significant interactions were seen when Atorvastatin was administered with antihypertensives or hypoglycemic agents. Patients should be closely monitored if Atorvastatin is added to digoxin, erythromycin, oral contraceptives, colestipol, antacid and warfarin.ContraindicationsATV 10 mg should not be used in patient with hypersensitivity to any component of this medication. It's contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. It is also contraindicated in patient with history of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors.Side Effects of ATV 10 mgATV 10 mg is generally well-tolerated. The most frequent side effects related to ATV 10 mg are constipation, flatulence, dyspepsia, abdominal pain. Other side effects includes infection, headache, back pain, rash, asthenia, arthralgia, myalgia.Pregnancy & LactationATV 10 mg is contraindicated in pregnancy and while breast-feeding. Women of child bearing potential should use appropriate contraceptive measures during Atorvastatin therapy. If the woman become pregnant while taking ATV 10 mg, it should be discontinued.Precautions & WarningsLiver effects: Liver function tests should be performed before the initiation of treatment and periodically thereafter. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.Overdose Effects of ATV 10 mgSpecific treatment is not available for atorvastatin overdose. The patient should be treated symptomatically and supportive measures instituted, as required. Liver function tests should be performed and serum CK levels should be monitored. Due to extensive atorvastatin binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Use In Special PopulationsGeriatric Use: Of the 39,828 patients who received Atorvastatin in clinicalstudies, 15,813 (40%) were ?65 years old and 2,800 (7%) were ?75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinicalexperience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (?65 years) is a predisposing factor for myopathy, Atorvastatin?should be prescribed with caution in the elderly.Hepatic Impairment: Atorvastatin?is contraindicated in patients with active liver disease whichmay include unexplained persistent elevations in hepatic transaminase levelsDrug ClassesOther Anti-anginal & Anti-ischaemic drugs, StatinsMode Of ActionAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.PregnancyPregnancy: Atorvastatin is contraindicated during pregnancy. Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction. Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atorvastatin should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with atorvastatin should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnantLactation: It is not known whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. Because of the potential for serious adverse reactions, women taking atorvastatin should not breastfeed their infants. Atorvastatin is contraindicated during breastfeeding.Pediatric UsesHepatic impairment: ATV 10 mg should be used with caution in patients with hepatic impairment. Pediatric use: For patients aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day with titration up to 20 mg per day. ATV 10 mg is not indicated in the treatment of patients below the age of 10 years.
ATV10 mg
Original price was: ₦2,750.00.₦2,475.00Current price is: ₦2,475.00. -
SaleATV 20 mgATV 20 mg is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo-B) and triglycerides levels in following diseases when response to diet and other non-pharmacological measures is inadequate. To reduce total cholesterol and LDL cholesterol in patients with heterozygous and homozygous familial hypercholesterolaemia. To reduce elevated cholesterol and triglycerides in patient with mixed dyslipidemia (Fredrickson Type Ia and Ib). For the treatment of patients with elevated serum triglyceride levels in hypertriglyceridaemia (Fredrickson Type IV). For the treatment of patients with dysbetalipoproteinaemia (Fredrickson Type III). To reduce cardiac ischaemic events in patients with asymptomatic or mild to moderate symptomatic coronary artery disease with elevated LDL-cholesterol level. To reduce total and LDL-cholesterol concentrations patients with hypercholesterolemia associated with or exacerbated by diabetes mellitus or renal transplantation.Theropeutic ClassOther Anti-anginal & Anti-ischaemic drugs, StatinsPharmacologyAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.Dosage & Administration of ATV 20 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Dosage of ATV 20 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Interaction of ATV 20 mgThe risk of myopathy during treatment with Atorvastatin is increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, azole antifungals and niacin. No clinically significant interactions were seen when Atorvastatin was administered with antihypertensives or hypoglycemic agents. Patients should be closely monitored if Atorvastatin is added to digoxin, erythromycin, oral contraceptives, colestipol, antacid and warfarin.ContraindicationsATV 20 mg should not be used in patient with hypersensitivity to any component of this medication. It's contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. It is also contraindicated in patient with history of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors.Side Effects of ATV 20 mgATV 20 mg is generally well-tolerated. The most frequent side effects related to ATV 20 mg are constipation, flatulence, dyspepsia, abdominal pain. Other side effects includes infection, headache, back pain, rash, asthenia, arthralgia, myalgia.Pregnancy & LactationATV 20 mg is contraindicated in pregnancy and while breast-feeding. Women of child bearing potential should use appropriate contraceptive measures during Atorvastatin therapy. If the woman become pregnant while taking ATV 20 mg, it should be discontinued.Precautions & WarningsLiver effects: Liver function tests should be performed before the initiation of treatment and periodically thereafter. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.Overdose Effects of ATV 20 mgSpecific treatment is not available for atorvastatin overdose. The patient should be treated symptomatically and supportive measures instituted, as required. Liver function tests should be performed and serum CK levels should be monitored. Due to extensive atorvastatin binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Use In Special PopulationsGeriatric Use: Of the 39,828 patients who received Atorvastatin in clinicalstudies, 15,813 (40%) were ?65 years old and 2,800 (7%) were ?75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinicalexperience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (?65 years) is a predisposing factor for myopathy, Atorvastatin?should be prescribed with caution in the elderly.Hepatic Impairment: Atorvastatin?is contraindicated in patients with active liver disease whichmay include unexplained persistent elevations in hepatic transaminase levelsDrug ClassesOther Anti-anginal & Anti-ischaemic drugs, StatinsMode Of ActionAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.PregnancyPregnancy: Atorvastatin is contraindicated during pregnancy. Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction. Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atorvastatin should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with atorvastatin should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnantLactation: It is not known whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. Because of the potential for serious adverse reactions, women taking atorvastatin should not breastfeed their infants. Atorvastatin is contraindicated during breastfeeding.Pediatric UsesHepatic impairment: ATV 20 mg should be used with caution in patients with hepatic impairment. Pediatric use: For patients aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day with titration up to 20 mg per day. ATV 20 mg is not indicated in the treatment of patients below the age of 10 years.
ATV20 mg
Original price was: ₦5,500.00.₦4,950.00Current price is: ₦4,950.00. -
SaleATV 40 mgATV 40 mg is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo-B) and triglycerides levels in following diseases when response to diet and other non-pharmacological measures is inadequate. To reduce total cholesterol and LDL cholesterol in patients with heterozygous and homozygous familial hypercholesterolaemia. To reduce elevated cholesterol and triglycerides in patient with mixed dyslipidemia (Fredrickson Type Ia and Ib). For the treatment of patients with elevated serum triglyceride levels in hypertriglyceridaemia (Fredrickson Type IV). For the treatment of patients with dysbetalipoproteinaemia (Fredrickson Type III). To reduce cardiac ischaemic events in patients with asymptomatic or mild to moderate symptomatic coronary artery disease with elevated LDL-cholesterol level. To reduce total and LDL-cholesterol concentrations patients with hypercholesterolemia associated with or exacerbated by diabetes mellitus or renal transplantation.Theropeutic ClassOther Anti-anginal & Anti-ischaemic drugs, StatinsPharmacologyAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.Dosage & Administration of ATV 40 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Dosage of ATV 40 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Interaction of ATV 40 mgThe risk of myopathy during treatment with Atorvastatin is increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, azole antifungals and niacin. No clinically significant interactions were seen when Atorvastatin was administered with antihypertensives or hypoglycemic agents. Patients should be closely monitored if Atorvastatin is added to digoxin, erythromycin, oral contraceptives, colestipol, antacid and warfarin.ContraindicationsATV 40 mg should not be used in patient with hypersensitivity to any component of this medication. It's contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. It is also contraindicated in patient with history of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors.Side Effects of ATV 40 mgATV 40 mg is generally well-tolerated. The most frequent side effects related to ATV 40 mg are constipation, flatulence, dyspepsia, abdominal pain. Other side effects includes infection, headache, back pain, rash, asthenia, arthralgia, myalgia.Pregnancy & LactationATV 40 mg is contraindicated in pregnancy and while breast-feeding. Women of child bearing potential should use appropriate contraceptive measures during Atorvastatin therapy. If the woman become pregnant while taking ATV 40 mg, it should be discontinued.Precautions & WarningsLiver effects: Liver function tests should be performed before the initiation of treatment and periodically thereafter. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.Overdose Effects of ATV 40 mgSpecific treatment is not available for atorvastatin overdose. The patient should be treated symptomatically and supportive measures instituted, as required. Liver function tests should be performed and serum CK levels should be monitored. Due to extensive atorvastatin binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Use In Special PopulationsGeriatric Use: Of the 39,828 patients who received Atorvastatin in clinicalstudies, 15,813 (40%) were ?65 years old and 2,800 (7%) were ?75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinicalexperience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (?65 years) is a predisposing factor for myopathy, Atorvastatin?should be prescribed with caution in the elderly.Hepatic Impairment: Atorvastatin?is contraindicated in patients with active liver disease whichmay include unexplained persistent elevations in hepatic transaminase levelsDrug ClassesOther Anti-anginal & Anti-ischaemic drugs, StatinsMode Of ActionAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.PregnancyPregnancy: Atorvastatin is contraindicated during pregnancy. Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction. Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atorvastatin should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with atorvastatin should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnantLactation: It is not known whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. Because of the potential for serious adverse reactions, women taking atorvastatin should not breastfeed their infants. Atorvastatin is contraindicated during breastfeeding.Pediatric UsesHepatic impairment: ATV 40 mg should be used with caution in patients with hepatic impairment. Pediatric use: For patients aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day with titration up to 20 mg per day. ATV 40 mg is not indicated in the treatment of patients below the age of 10 years.
ATV40 mg
Original price was: ₦8,250.00.₦7,425.00Current price is: ₦7,425.00. -
SaleAugment 1 gmCo-amoxiclav is indicated for short-term treatment of bacterial infections at the following sites: Upper respiratory tract infections (including ENT) e.g.tonsillitis,sinusitis,otitis media. Lower respiratory tract infections e.g.acute and chronic bronchitis, lobar and bronchopneumonia. ... Read moreCo-amoxiclav is indicated for short-term treatment of bacterial infections at the following sites: Upper respiratory tract infections (including ENT) e.g.tonsillitis,sinusitis,otitis media. Lower respiratory tract infections e.g.acute and chronic bronchitis, lobar and bronchopneumonia. Genito-urinary tract infections e.g.cystitis,urethritis,pyelonephritis. Skin and soft tissue infections. Bone and joint infections e.g.osteomyelitis. Other infections e.g.septic abortion,puerperal sepsis,intra-abdominal sepsis etc. Composition 375 mg tablet: Each film coated tablet contains Amoxicillin 250 mg as Amoxicillin Trihydrate BP and Clavulanic Acid 125 mg as Diluted Potassium Clavulanate BP. 625 mg tablet: Each film coated tablet contains Amoxicillin 500 mg as Amoxicillin Trihydrate BP and Clavulanic Acid 125 mg as Diluted Potassium Clavulanate BP. 1 gm tablet: Each film coated tablet contains Amoxicillin 875 mg as Amoxicillin Trihydrate BP and Clavulanic Acid 125 mg Diluted Potassium Clavulanate BP. Powder for Suspension: Each 5 ml reconstituted suspension contains Amoxicillin 125 mg as Amoxicillin Trihydrate BP and Clavulanic Acid 31.25 mg as Diluted Potassium Clavulanate BP. Powder for Suspension (Forte): Each 5 ml reconstituted suspension contains Amoxicillin 400 mg as Amoxicillin Trihydrate BP and Clavulanic Acid 57.5 mg as Diluted Potassium Clavulanate BP. 1.2 gm Injection: Each vial contains sterile mixture of Amoxicillin Sodium BP (equivalent to Amoxicillin 1 gm) and Clavulanate Potassium USP (equivalent to Clavulanic Acid 200 mg). 0.6 gm injection: Each vial contains sterile mixture of Amoxicillin Sodium BP (equivalent to Amoxicillin 500) and Clavulanate Potassium USP (equivalent to Clavulanic Acid 100 mg). Theropeutic ClassBroad spectrum penicillinsPharmacologyAmoxycillin & Clavulanic Acidis an antibacterial combination consisting of the antibiotic Amoxicillin and the beta-lactamase inhibitor Clavulanic Acid. Amoxicillin has a broad spectrum of bactericidal activity against many Gram-positive & Gram-negative microorganisms but it is susceptible to degradation by beta-lactamases and therefore the spectrum of activity does not include microorganisms, which produce these enzymes. Clavulanic acid possesses the ability to inactivate a wide range of beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. Thus Clavulanic acid in combination of Amoxicillin and Clavulanic acid protects Amoxicillin from degradation by beta-lactamase enzymes and effectively extends the antibiotic spectrum to embrace a wide range of microorganisms.Dosage & Administration of Augment 1 gmOral: Adults and children over 12 years: One 375 mg tablet 3 times a day. In severe infection one 625 mg tablet 3 times a day or one 1 gm tablet two times a day. Children of 6-12 years: 2 teaspoonful Powder for Suspension every 8 hours. Children of 1 -6 years: 1 teaspoonful Powder for Suspension every 8 hours. Children below 1 year: 25 mg/kg/day in divided doses every 8 hours. IV Injection: Adults and children over 12 years: 1.2 g every 6-8 hours Children up to 3 months: 30 mg/kg every 8 hours (every 12 hours in the perinatal period and in premature infants) Child 3 months to 12 years: 30 mg/kg every 6-8 hours. Dosage of Augment 1 gmAdults and children over 12 years:Tablet: The usual adult dose is one 625 mg Tablet every 12 hours or one 375 mg Tablet every 8 hours. For more severe infections and infections of the respiratory tract, the dose should be one 1 gm Tablet every 12 hours or one 625 mg Tablet every 8 hours. Suspension: Children 6-12 years: 2 teaspoonful every 8 hours. Children 1-6years: 1 teaspoonful every 8 hours. Children below 1 year: 25 mg/kg/day in divided doses every 8 hours, for example a 7.5 kg child would require 2 ml suspension t.i.d, Treatment should not be extended beyond 14 days without review. Forte suspension: The usual recommended daily dosage: 25/3.6 mg/kg/day in mild to moderate infections (upper respiratory tract infections e.g. recurrent tonsilitis, lower respiratory infections, and skin and soft tissue infections)? For serious infections: 45/6.4 mg/kg/day for the treatment of more serious infections (upper respiratory tract infections, e.g. otitis media and sinusitis, lower respiratory infections e.g. bronchopneumonia, and urinary tract infections). Children of 2 to 12 years:Mild to moderate infections: 25/3.6 mg/kg/day (Suspension) 2-6 years (13-21 kg) 2.5 ml suspension b.i.d 7-12years (22-40kg) 5 ml suspension b.i.d Serious infections: 45/6.4 mg/kg/day (Forte Suspension) 2-6 years (13-21 kg) 5 ml suspension b.i.d 7-12 years (22-40 kg) 10 ml suspension b.i.d IV InjectionAdults- Usually, 1.2 gm every 8 hours Increased in more serious infections to 1.2 gm every 6 hours For surgical prophylaxis: The usual dose is 1.2 gm at induction, for high risk procedures (eg. colorectal surgery) up to 2-3 gm may be given every 8 hours. Children- 0 to 3 months: 30 mg/kg every 8 hours. (every 12 hours in the perinatal period and in premature infants. 3 months to 12 years: Usually 30 mg/kg every 8 hours increased in more serious infection to 30 mg/kg every 6 hours. Administration of Augment 1 gmOral dosage form: This may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when Amoxicillin and Clavulanic acid are administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, Amoxicillin and Clavulanic acid should be taken at the start of the meal.IV injection is not suitable for intramuscular or subcutaneous administration. The reconstituted vial can be administered intravenously by injection (over 2 minutes) or slow intravenous infusion (30 minutes). The contents of the content of the vial must be used within 20 minutes and thereafter any unused material should be discarded.Interaction of Augment 1 gmProlongation of bleeding time and prothrombin time have been reported in some patients receiving Co-amoxiclav. In common with other broad-spectrum antibiotics, Co-amoxiclav may reduce the efficacy of oral contraceptives and patients should be warned accordingly. Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions. There are no data on the concomitant use of Co-amoxiclav and allopurinol.ContraindicationsHistory of Penicillin hypersensitivity. Attention should be paid to possible cross-sensitivity with other beta-lactam antibiotics e.g. cephalosporins. Also contraindicated for patients with a previous history of Co-amoxiclav or Penicillin-associated cholestatic jaundice.Side Effects of Augment 1 gmSide effects, as with Amoxicillin, are uncommon and mainly of a mild and transitory nature. Diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking Co-amoxiclav at the start of meals. Hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. Urticarial and erythematous rashes sometimes occur. Rarely erythema multiforme, Stevens-Johnson Syndrome and exfoliative dermatitis have been reported. In common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported.Pregnancy & LactationAmoxicillin and Clavulanic acid has been used orally in human pregnancy in a limited number of cases with no untoward effect; however use of Amoxycillin & Clavulanic Acid in pregnancy is not recommended unless considered essential by the physician. During lactation, trace quantities of Amoxicillin can be detected in breast milk.Precautions & WarningsCo-amoxiclav should be used with care in patients on anticoagulation therapy or with severe hepatic dysfunction. In patients with moderate or severe renal impairment, dosage should be adjusted. During the administration of a high dose of Co-amoxiclav adequate fluid intake and urinary output should be maintained to minimize the possibility of crystalluria.Overdose Effects of Augment 1 gmProblems of overdose with Co-amoxiclav are unlikely to occur, if encountered gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Co-amoxiclav may be removed from the circulation by haemodialysis.Storage ConditionsThis should be stored below 25?C, protected from light and moisture. Once reconstituted suspension should be kept in the refrigerator (but not frozen) and should be usedby 7 days. Once reconstituted vial must be used within 20 minutes.Use In Special PopulationsDosage in renal impairment: The dose should be adjusted in case of patients with renal impairment.Adults or?Children: Mild impairment (CrCl > 30 ml/min): No change in dose. Moderate impairment (CrCl 10- 30 ml/min): 625 mg tablet 12 hourly. Severe impairment (CrCl 30ml/minute): No changein dosage. Moderate impairment (Creatinine clearance 10-30 ml/minute): One 375 Tablet or one 625 Tablet 12 hourly or 1.2 gm IV followed by 0.6 gm IV 12 hourly. Severe impairment (Creatinine clearance <10 ml/minute): Not more than one 375 mg tablet 12 hourly or 1.2 gm IV followed by 0.6 gm IV 24 hourly. Dialysis decreases serum concentrations of this preparation and an additional 0.6 gm IV dose may need to be given during dialysis and at the end of dialysis. Children: A similar reduction in dosage should be made for children. Administration hepatic impairment: Dose with caution; monitor hepatic function at regular intervals.
Augment1 gm
Original price was: ₦2,200.00.₦2,002.00Current price is: ₦2,002.00. -
SaleAugment 625 mgCo-amoxiclav is indicated for short-term treatment of bacterial infections at the following sites: Upper respiratory tract infections (including ENT) e.g.tonsillitis,sinusitis,otitis media. Lower respiratory tract infections e.g.acute and chronic bronchitis, lobar and bronchopneumonia. ... Read moreCo-amoxiclav is indicated for short-term treatment of bacterial infections at the following sites: Upper respiratory tract infections (including ENT) e.g.tonsillitis,sinusitis,otitis media. Lower respiratory tract infections e.g.acute and chronic bronchitis, lobar and bronchopneumonia. Genito-urinary tract infections e.g.cystitis,urethritis,pyelonephritis. Skin and soft tissue infections. Bone and joint infections e.g.osteomyelitis. Other infections e.g.septic abortion,puerperal sepsis,intra-abdominal sepsis etc. Composition 375 mg tablet: Each film coated tablet contains Amoxicillin 250 mg as Amoxicillin Trihydrate BP and Clavulanic Acid 125 mg as Diluted Potassium Clavulanate BP. 625 mg tablet: Each film coated tablet contains Amoxicillin 500 mg as Amoxicillin Trihydrate BP and Clavulanic Acid 125 mg as Diluted Potassium Clavulanate BP. 1 gm tablet: Each film coated tablet contains Amoxicillin 875 mg as Amoxicillin Trihydrate BP and Clavulanic Acid 125 mg Diluted Potassium Clavulanate BP. Powder for Suspension: Each 5 ml reconstituted suspension contains Amoxicillin 125 mg as Amoxicillin Trihydrate BP and Clavulanic Acid 31.25 mg as Diluted Potassium Clavulanate BP. Powder for Suspension (Forte): Each 5 ml reconstituted suspension contains Amoxicillin 400 mg as Amoxicillin Trihydrate BP and Clavulanic Acid 57.5 mg as Diluted Potassium Clavulanate BP. 1.2 gm Injection: Each vial contains sterile mixture of Amoxicillin Sodium BP (equivalent to Amoxicillin 1 gm) and Clavulanate Potassium USP (equivalent to Clavulanic Acid 200 mg). 0.6 gm injection: Each vial contains sterile mixture of Amoxicillin Sodium BP (equivalent to Amoxicillin 500) and Clavulanate Potassium USP (equivalent to Clavulanic Acid 100 mg). Theropeutic ClassBroad spectrum penicillinsPharmacologyAmoxycillin & Clavulanic Acidis an antibacterial combination consisting of the antibiotic Amoxicillin and the beta-lactamase inhibitor Clavulanic Acid. Amoxicillin has a broad spectrum of bactericidal activity against many Gram-positive & Gram-negative microorganisms but it is susceptible to degradation by beta-lactamases and therefore the spectrum of activity does not include microorganisms, which produce these enzymes. Clavulanic acid possesses the ability to inactivate a wide range of beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. Thus Clavulanic acid in combination of Amoxicillin and Clavulanic acid protects Amoxicillin from degradation by beta-lactamase enzymes and effectively extends the antibiotic spectrum to embrace a wide range of microorganisms.Dosage & Administration of Augment 625 mgOral: Adults and children over 12 years: One 375 mg tablet 3 times a day. In severe infection one 625 mg tablet 3 times a day or one 1 gm tablet two times a day. Children of 6-12 years: 2 teaspoonful Powder for Suspension every 8 hours. Children of 1 -6 years: 1 teaspoonful Powder for Suspension every 8 hours. Children below 1 year: 25 mg/kg/day in divided doses every 8 hours. IV Injection: Adults and children over 12 years: 1.2 g every 6-8 hours Children up to 3 months: 30 mg/kg every 8 hours (every 12 hours in the perinatal period and in premature infants) Child 3 months to 12 years: 30 mg/kg every 6-8 hours. Dosage of Augment 625 mgAdults and children over 12 years:Tablet: The usual adult dose is one 625 mg Tablet every 12 hours or one 375 mg Tablet every 8 hours. For more severe infections and infections of the respiratory tract, the dose should be one 1 gm Tablet every 12 hours or one 625 mg Tablet every 8 hours. Suspension: Children 6-12 years: 2 teaspoonful every 8 hours. Children 1-6years: 1 teaspoonful every 8 hours. Children below 1 year: 25 mg/kg/day in divided doses every 8 hours, for example a 7.5 kg child would require 2 ml suspension t.i.d, Treatment should not be extended beyond 14 days without review. Forte suspension: The usual recommended daily dosage: 25/3.6 mg/kg/day in mild to moderate infections (upper respiratory tract infections e.g. recurrent tonsilitis, lower respiratory infections, and skin and soft tissue infections)? For serious infections: 45/6.4 mg/kg/day for the treatment of more serious infections (upper respiratory tract infections, e.g. otitis media and sinusitis, lower respiratory infections e.g. bronchopneumonia, and urinary tract infections). Children of 2 to 12 years:Mild to moderate infections: 25/3.6 mg/kg/day (Suspension) 2-6 years (13-21 kg) 2.5 ml suspension b.i.d 7-12years (22-40kg) 5 ml suspension b.i.d Serious infections: 45/6.4 mg/kg/day (Forte Suspension) 2-6 years (13-21 kg) 5 ml suspension b.i.d 7-12 years (22-40 kg) 10 ml suspension b.i.d IV InjectionAdults- Usually, 1.2 gm every 8 hours Increased in more serious infections to 1.2 gm every 6 hours For surgical prophylaxis: The usual dose is 1.2 gm at induction, for high risk procedures (eg. colorectal surgery) up to 2-3 gm may be given every 8 hours. Children- 0 to 3 months: 30 mg/kg every 8 hours. (every 12 hours in the perinatal period and in premature infants. 3 months to 12 years: Usually 30 mg/kg every 8 hours increased in more serious infection to 30 mg/kg every 6 hours. Administration of Augment 625 mgOral dosage form: This may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when Amoxicillin and Clavulanic acid are administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, Amoxicillin and Clavulanic acid should be taken at the start of the meal.IV injection is not suitable for intramuscular or subcutaneous administration. The reconstituted vial can be administered intravenously by injection (over 2 minutes) or slow intravenous infusion (30 minutes). The contents of the content of the vial must be used within 20 minutes and thereafter any unused material should be discarded.Interaction of Augment 625 mgProlongation of bleeding time and prothrombin time have been reported in some patients receiving Co-amoxiclav. In common with other broad-spectrum antibiotics, Co-amoxiclav may reduce the efficacy of oral contraceptives and patients should be warned accordingly. Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions. There are no data on the concomitant use of Co-amoxiclav and allopurinol.ContraindicationsHistory of Penicillin hypersensitivity. Attention should be paid to possible cross-sensitivity with other beta-lactam antibiotics e.g. cephalosporins. Also contraindicated for patients with a previous history of Co-amoxiclav or Penicillin-associated cholestatic jaundice.Side Effects of Augment 625 mgSide effects, as with Amoxicillin, are uncommon and mainly of a mild and transitory nature. Diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking Co-amoxiclav at the start of meals. Hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. Urticarial and erythematous rashes sometimes occur. Rarely erythema multiforme, Stevens-Johnson Syndrome and exfoliative dermatitis have been reported. In common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported.Pregnancy & LactationAmoxicillin and Clavulanic acid has been used orally in human pregnancy in a limited number of cases with no untoward effect; however use of Amoxycillin & Clavulanic Acid in pregnancy is not recommended unless considered essential by the physician. During lactation, trace quantities of Amoxicillin can be detected in breast milk.Precautions & WarningsCo-amoxiclav should be used with care in patients on anticoagulation therapy or with severe hepatic dysfunction. In patients with moderate or severe renal impairment, dosage should be adjusted. During the administration of a high dose of Co-amoxiclav adequate fluid intake and urinary output should be maintained to minimize the possibility of crystalluria.Overdose Effects of Augment 625 mgProblems of overdose with Co-amoxiclav are unlikely to occur, if encountered gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Co-amoxiclav may be removed from the circulation by haemodialysis.Storage ConditionsThis should be stored below 25?C, protected from light and moisture. Once reconstituted suspension should be kept in the refrigerator (but not frozen) and should be usedby 7 days. Once reconstituted vial must be used within 20 minutes.Use In Special PopulationsDosage in renal impairment: The dose should be adjusted in case of patients with renal impairment.Adults or?Children: Mild impairment (CrCl > 30 ml/min): No change in dose. Moderate impairment (CrCl 10- 30 ml/min): 625 mg tablet 12 hourly. Severe impairment (CrCl 30ml/minute): No changein dosage. Moderate impairment (Creatinine clearance 10-30 ml/minute): One 375 Tablet or one 625 Tablet 12 hourly or 1.2 gm IV followed by 0.6 gm IV 12 hourly. Severe impairment (Creatinine clearance <10 ml/minute): Not more than one 375 mg tablet 12 hourly or 1.2 gm IV followed by 0.6 gm IV 24 hourly. Dialysis decreases serum concentrations of this preparation and an additional 0.6 gm IV dose may need to be given during dialysis and at the end of dialysis. Children: A similar reduction in dosage should be made for children. Administration hepatic impairment: Dose with caution; monitor hepatic function at regular intervals.
Augment625 mg
Original price was: ₦1,760.00.₦1,601.60Current price is: ₦1,601.60. -
SaleAutotear 0.4%+0.3%This sterile eye drops is indicated for the temporary relief of burning and irritation due to dryness of the eye.Theropeutic ClassDrugs for Dry eyesPharmacologyThe mechanism of action is thought to be due to its unique gelling and lubricating system formulated to adjust to each user's individual tear PH. When Polyethylene Glycol & Propylene Glycol combine with natural tears, a soft gel forms a network of protection over the eye surface. Since it promotes a healthy environment in eye surface, damaged surface cells of eye can repair more easily.Dosage & Administration of Autotear 0.4%+0.3%The frequency of instillation of drops and the duration of treatment will vary depending upon the severity of the underlying condition and the response to treatment. Usually instill 1 or 2 drops in the affected eyes.Dosage of Autotear 0.4%+0.3%Instill 1 drop 4 times daily in the affected eye(s) or as needed.ContraindicationsIt is contraindicated in patients with known hypersensitivity to any ingredient in this formulation.Side Effects of Autotear 0.4%+0.3%Generally well tolerated. This sterile eye drops should not be used if allergic condition occurs to any ingredients of the product.Pregnancy & LactationPregnancy: Due to the negligible systemic exposure and the lack of pharmacological activity, this medication can be used during pregnancy.Nursing Mothers: It is not known whether this medication is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is applied to a nursing woman.Precautions & WarningsNever touch the tip of the container with any surface to avoid contamination. Replace cap after each use.Storage ConditionsStore in a cool & dry place, protect from light. Do not use longer than one month after the first opening. Keep out of the reach of childrenUse In Special PopulationsPediatric Use: Safety and efficacy in pediatric patients have not been established.Drug ClassesDrugs for Dry eyesMode Of ActionThe combination of Polyethylene Glycol 400 & Propylene Glycol is clinically proven to reduce both signs and symptoms of dry eye. The mechanism of action is thought to be due to its unique gelling and lubricating system formulated to adjust to each users individual tear pH. When the ingredients of this eye drops combine with natural tears, a soft gel forms a network of protection over the eye surface. Since it promotes a healthy environment in eye surfaces, damaged surface cells of eye can repair more easily.
Autotear0.4%+0.3%
Original price was: ₦13,750.00.₦12,375.00Current price is: ₦12,375.00. -
SaleAvanza 2 mgAvanza 2 mg is indicated to- Strong antioxidant Improves cardiovascular health (Atherosclerosis, reduce cholesterol) Improves immune function Improves condition of skin Protects skin from damage caused by sun (Reduces wrinkles, pimples and other signs of aging) ... Read moreAvanza 2 mg is indicated to- Strong antioxidant Improves cardiovascular health (Atherosclerosis, reduce cholesterol) Improves immune function Improves condition of skin Protects skin from damage caused by sun (Reduces wrinkles, pimples and other signs of aging) Improves recovery from central nervous system injuries Protects from Parkinson?s disease, Dementia and Alzheimer's disease Protects eyes from cataracts and macular degeneration Reduces inflammation (Arthritis) Reduces risk of infertility Also Avanza 2 mg effectively reduces oxidative damage to DNA, decreases the risk for many typesof cancer and stabilizes blood sugar.Theropeutic ClassSupplements & adjuvant therapyPharmacologyAvanza 2 mg acts as an antioxidant by dual mode of action. It suppresses singlet oxygen and also inhibits lipid peroxidation. By these actions it reduces the harmful free radicals. Therefore acts as a very strong antioxidant. Avanza 2 mg is absorbed by passive diffusion into the intestinal epithelium alongside fatty acids. Then it is incorporated into lipoproteins, transported to the liver, via lymph and blood and partly resecreted with lipoproteins. More than 70% of the Avanza 2 mg is contained in high density lipoprotein part of plasma. Highest concentration of Avanza 2 mg is in the small intestine, followed by subcutaneous fat, spleen, liver, heart, kidney and skin and lowest in the muscles.Dosage & Administration of Avanza 2 mgAdults (18 years and older)- Daily dose is 4 mg. should be taken along with or immediately prior to meals in the morning. Different dose for various use are given below: 2-4 mg: Used as a strong antioxidant, improves cardiovascular health (Atherosclerosis, reduce cholesterol), improves immune function. 4-8 mg: Improves condition of skin, protects skin from sun damage (Reduce wrinkles, pimples and other signs of aging), improves recovery from central nervous system injuries and protects eyes from cataracts and macular degeneration. 8-12 mg: Reduces inflammation (Arthritis) 16 mg: Reduces risk of infertility Dosage of Avanza 2 mgAdults (18 years and older): Daily dose is 4 mg. Should be taken along with or immediately prior to meals in the morning. 4 mg: As a strong antioxidant, improves cardiovascular health (Atherosclerosis, reduce cholesterol), improves immune function. 4-8 mg: Improves condition of skin, protects skin from sun damage (Reduce wrinkles, pimples and other signs of aging), improves recovery from central nervous systehn injuries and protects eyes from cataracts and macular degeneration. 8-12 mg: Reduces inflammation (Arthritis) 16 mg: Reduces risk of infertility Interaction of Avanza 2 mgConcomitant intake of Avanza 2 mg with Cholestyramine, Colestipol, Mineral oil, Orlistat may reduce the absorption rate of Avanza 2 mg.ContraindicationsContraindicated for those with known allergies to Avanza 2 mg.Side Effects of Avanza 2 mgNo severe side effects have been reported yet.Pregnancy & LactationBoth pregnant women and lactating mothers should avoid Avanza 2 mg supplements as no data on safety has been found yetPrecautions & WarningsPregnant women and nursing mothers should avoid Avanza 2 mg containing supplements.Overdose Effects of Avanza 2 mgNo case of overdose has occurred with Avanza 2 mg.Storage ConditionsStore in cool and dry place, away from direct light. Keep out of reach of children.Drug ClassesSupplements & adjuvant therapyMode Of ActionAvanza 2 mg acts as an antioxidant by dual mode of action. It suppresses singlet oxygen and also inhibits lipid peroxidation. By these actions it reduces the harmful free radicals. Therefore acts as a very strong antioxidant. Avanza 2 mg is absorbed by passive diffusion into the intestinal epithelium alongside fatty acids. Then it is incorporated into lipoproteins, transported to the liver, via lymph and blood and partly resecreted with lipoproteins. More than 70% of the Avanza 2 mg is contained in high-density lipoprotein part of plasma. Highest concentration of Avanza 2 mg is in the small intestine, followed by subcutaneous fat, abdominal fat, spleen, liver, heart, kidney and skin and lowest in the muscles.PregnancyBoth pregnant women and lactating mothers should avoid Avanza 2 mg supplements as no data on safety has been found yet.
Avanza2 mg
Original price was: ₦660.00.₦607.20Current price is: ₦607.20.